Ravi A. Madan, M.D.

Dr. Madan is the clinical director of the Genitourinary Malignancies Branch. His clinical research is focused on immune stimulating therapies and prostate cancer. Specifically, Dr. Madan’s clinical trials are designed to develop a better understanding of how immune stimulating therapies can improve clinical outcomes and be combined with other therapies. In addition to investigating emerging therapeutics in all stages of prostate cancer, Dr. Madan is exploring immunotherapy treatment strategies in rare tumors such as medullary thyroid cancer.
1) immunotherapy, 2) prostate cancer, 3) therapeutic cancer vaccines, 4) immune check point inhibitors, 5) metastatic prostate cancer, 6) medullary thyroid cancer
Contact Info
Center for Cancer Research
National Cancer Institute
Building 10, Room 13N240B
Bethesda, MD 20892
Ph: 301-480-7168
Fax: 301-480-8867
madanr@mail.nih.gov
-
A Phase I/II Study of Bintrafusp alfa (M7824) and M9241 in Combination with Docetaxel in Adults with Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
Open - Not yet RecruitingNCI Protocol ID NCI-21-C-0001Investigator Ravi A. Madan, M.D. -
Radium-223 in Biochemically Recurrent Prostate Cancer
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-20-C-0100Investigator Ravi A. Madan, M.D.Share this trial: Referral ContactsContact Name Phone Number Anna Couvillon 240-858-3148 Ravi Madan 301-480-7168 -
Radium-223 in Biochemically Recurrent Prostate Cancer
Open - RecruitingNCI Protocol ID NCI-20-C-0010Investigator Ravi A. Madan, M.D.Share this trial: Referral ContactsContact Name Phone Number Anna Couvillon 240-858-3148 Ravi Madan 301-480-7168 -
A Single Arm Pilot Study Combining CRLX101, a Nanoparticle Camptothecin, with Enzalutamide in Patients with Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
Open - RecruitingNCI Protocol ID NCI-18-C-0096Investigator Ravi A. Madan, M.D. -
Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
Open - RecruitingNCI Protocol ID NCI-18-C-0005Investigator Ravi A. Madan, M.D.
Selected Publications
- J Natl Cancer Inst. [Epub ahead of print], 2020. [ Journal Article ]
- Eur Urol. 77(1): 36-7, 2020. [ Journal Article ]
- J Immunother Cancer. 7(1): 269, 2019. [ Journal Article ]
- Nat Rev Urol. 15(10): 593-4, 2018. [ Journal Article ]
- Clin Cancer Res. 24(6): 1287-95, 2018. [ Journal Article ]
Dr. Madan is an Assistant Clinical Investigator at the National Cancer Institute (NCI), conducting clinical research in therapeutic cancer vaccines and genitourinary malignancies. Dr. Madan received his M.D. from the UMDNJ-New Jersey Medical School in 2001 and completed his internal medicine residency at UMDNJ-University Hospital in June 2004. He joined the NCI Medical Oncology Branch as an oncology/hematology fellow in 2005. He currently holds a joint appointment in the Medical Oncology Branch and the Laboratory of Tumor Immunology and Biology. His research interests are focused on immune stimulating therapeutic cancer vaccines and novel therapies in the treatment of prostate cancer.
Name | Position |
---|---|
Philip Arlen M.D. | Special Volunteer |
Guinevere Chun | Research Nurse |
Carlos Diaz | Patient Care Coordinator (Contr.) |
Amy Hankin PA-C, MMSc | Physician Assistant |
Elizabeth Lamping R.N., B.S.N. | Research Nurse |
Sheri McMahon R.N., B.S.N. | Research Nurse |
Michelle Ojemuyiwa M.D. | Clinical Collaborator |
Helen Owens | Research Nurse |
Lee Pai-Scherf M.D. | Clinical Collaborator |
Myrna Rauckhorst R.N. | Research Nurse |
Moniquea Smith | Patient Care Coordinator (Contr.) |
Marc Theoret M.D. | Clinical Collaborator |
Monique Williams N.P. | Nurse Practitioner (Contr.) |